What insurance policy changes affect HCPCS J9311?

There are 7 tracked policy changes affecting HCPCS J9311, including updates from Humana, BCBS Tennessee, Aetna. Each change may modify coverage criteria, reimbursement rates, or prior-authorization requirements.

Which payers have updated policy for HCPCS J9311?

Payers that have issued tracked updates for HCPCS J9311 include: Humana, BCBS Tennessee, Aetna, Florida Blue.

How do I get notified when HCPCS J9311 policy changes?

Create a free account at PolicyChanges.app and save a search filtered to HCPCS J9311. You will receive a daily digest email whenever a new policy change references this code.

Why do payers change policies for HCPCS J9311?

Payers revise policies for individual billing codes to align with updated clinical guidelines, CMS rule changes, fraud and abuse prevention measures, or network cost-management goals. Changes can affect medical necessity criteria, place-of-service restrictions, bundling rules, or whether a code requires prior authorization.

J9311 — Injection, rituximab 10 mg and hyaluronidase: Insurance Policy Changes

J9311 Insurance Policy Changes

HCPCS J9311 is officially defined as "Injection, rituximab 10 mg and hyaluronidase." HCPCS J9311 is referenced in 7 tracked payer policy changes from Humana, BCBS Tennessee, and 2 other payers. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for HCPCS J9311 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.

High impact

Carfilzomib (Kyprolis) (CPB 0845, reviewed 2026-03-02)

Aetna·Effective Mar 2, 2026

Aetna updated its Clinical Policy Bulletin 0845 for Carfilzomib (Kyprolis) effective March 2, 2026, establishing comprehensive coverage criteria for multiple myeloma, POEMS syndrome, plasma cell-related MIDD, plasma cell-related MGRS, systemic light chain amyloidosis, and Waldenstrom macroglobulinemia. Precertification is required for all Kyprolis use in multiple myeloma patients. The policy defines specific combination therapies, dosing limits, and experimental indications that will affect claims processing and prior authorization workflows.

J9311 Insurance Policy Changes

Adcetris® (brentuximab vedotin) (New)

Commercial BlueCare PAD_Step Therapy Guide

Belimumab (Benlysta) (CPB 0818, reviewed 2026-06-10)

Carfilzomib (Kyprolis) (CPB 0845, reviewed 2026-03-02)

Medicare Part B Step Therapy Product Updates

Datroway (datopotamab deruxtecan-dlnk)

Polatuzumab Vedotin-piiq (Polivy) (CPB 0955, reviewed 2025-03-13)